M. E. Williams Et Al. , "Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.31, Illinois, United States Of America, 2013
Williams, M. E. Et Al. 2013. Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Williams, M. E., Goy, A., Sinha, R., Besisik, S., Drach, J. W., Ramchandren, R., ... Zhang, L.(2013). Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study . 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Williams, Michael Et Al. "Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2013
Williams, Michael E. Et Al. "Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2013
Williams, M. E. Et Al. (2013) . "Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Michael E. Williams Et Al. }, title={Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study}, congress name={49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2013}}